Notification of Results

Oxford Biomedica PLC
07 February 2008


For Immediate Release                                           7 FEBRUARY 2008


             OXFORD BIOMEDICA: NOTICE OF FY2007 PRELIMINARY RESULTS
                                  AND WEBCAST
                                        
                                        
                              MONDAY 10 MARCH 2008


Oxford, UK - 7 February 2008: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, announces that it will be releasing its preliminary results for
the twelve months ended 31 December 2007 on Monday, 10 March 2008.

Analyst meeting: An analyst briefing will be held at 10:30 am on 10 March at the
offices of Buchanan Communications, 45 Moorfields, London EC2.

Web cast: Simultaneously to the analyst briefing at 10.30 am, there will be a
live audio web cast of the results presentation. To connect to the web cast
facility, please go to the Company's website: http://www.citycomments.co.uk
approximately 10 minutes (10.20 am) before the start of the briefing. This will
also be available for replay shortly after the presentation.

                                      -Ends-



For further information, please contact:
Oxford BioMedica plc:

Professor Alan Kingsman, Chief Executive            Tel: [phone]
JPMorgan Cazenove Limited:

James Mitford/ Gina Gibson                          Tel: [phone]
City/Financial Enquiries:

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson        Tel: [phone]
Buchanan Communications
Scientific/Trade Press Enquiries:

Gemma Price/ Holly Griffiths/ Katja Stout           Tel: [phone]

College Hill Life Sciences
US Enquiries:

Thomas Fechtner                                          Tel: [phone]

The Trout Group LLC


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in
cancer immunotherapy and gene-based therapies. The Company was established in
1995, as a spin-out from Oxford University, and is listed on the London Stock
Exchange.


The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. The lead product candidate is TroVax(R),
an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis
for global development and commercialisation. TroVax is in Phase III
development. Oxford BioMedica has three other products in clinical development,
including ProSavin(R), a novel gene-based treatment for Parkinson's disease, in
a Phase I/II trial. The Company is underpinned by over 80 patent families, which
represent one of the broadest patent estates in the field. The Company has a
staff of approximately 85. Oxford BioMedica has collaborations with
sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees
include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer.


Further information is available at www.oxfordbiomedica.co.uk






                      This information is provided by RNS
            The company news service from the London Stock Exchange